Cette recherche s'applique uniquement aux ressources en bibliothèque.
37 résultats
Trier par:
Ajouter à la liste:
    • Plusieurs versions

    In vitro evaluation of avidin antibody pretargeting using 211 At‐labeled and biotinylated poly‐L‐lysine as effector molecule

    Frost, Sofia Hl, Jensen, Holger, Lindegren, Sture
    Cancer, 15 February 2010, Vol.116(S4), pp.1101-1110 [Revue évaluée par les pairs]

    • Plusieurs versions

    Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

    Cederkrantz, Elin, Andersson, Håkan, Bernhardt, Peter, Bäck, Tom, Hultborn, Ragnar, Jacobsson, Lars, Jensen, Holger, Lindegren, Sture, Ljungberg, Michael, Magnander, Tobias, Palm, Stig, Albertsson, Per
    International journal of radiation oncology, biology, physics, 01 November 2015, Vol.93(3), pp.569-576 [Revue évaluée par les pairs]

    • Plusieurs versions

    N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides

    Aneheim, Emma, Foreman, Mark R. Stj, Jensen, Holger, Lindegren, Sture
    Applied radiation and isotopes, February 2015, Vol.96, pp.1-5 [Revue évaluée par les pairs]

    • Plusieurs versions

    Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb

    Eriksson, Sophie, Bäck, Tom, Elgström, Erika, Jensen, Holger, Nilsson, Rune, Lindegren, Sture, Tennvall, Jan
    EJNMMI Research, 2013, Vol.3(1), pp.1-9 [Revue évaluée par les pairs]

    • Plusieurs versions

    Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model

    Gustafsson, Anna M.E, Bäck, Tom, Elgqvist, Jörgen, Jacobsson, Lars, Hultborn, Ragnar, Albertsson, Per, Morgenstern, Alfred, Bruchertseifer, Frank, Jensen, Holger, Lindegren, Sture
    Nuclear medicine and biology, 2012, Vol.39(1), pp.15-22 [Revue évaluée par les pairs]

    • Plusieurs versions

    Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities

    Elgqvist, Jorgen, Ahlberg, Daniel, Andersson, Hakan, Jensen, Holger, Johansson, Bengt R, Kahu, Helena, Olsson, Marita, Lindegren, Sture
    World journal of oncology, June 2010, Vol.1(3), pp.101-110 [Revue évaluée par les pairs]

    • Plusieurs versions

    Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice

    Elgqvist, Jörgen, Andersson, Håkan, Jensen, Holger, Kahu, Helena, Lindegren, Sture, Warnhammar, Elisabet, Hultborn, Ragnar
    Journal of oncology, 2010, Vol.2010, pp.394913 [Revue évaluée par les pairs]

    • Plusieurs versions

    Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice

    Palm, Stig, Bäck, Tom, Claesson, Ingela, Danielsson, Anna, Elgqvist, Jörgen, Frost, Sofia, Hultborn, Ragnar, Jensen, Holger, Lindegren, Sture, Jacobsson, Lars
    International journal of radiation oncology, biology, physics, 2007, Vol.69(2), pp.572-579 [Revue évaluée par les pairs]

    • Plusieurs versions

    Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with {sup 211}At-MX35 F(ab'){sub 2}

    Elgqvist, Joergen, Andersson, Hakan, Bernhardt, Peter, Baeck, Tom, Claesson, Ingela, Hultborn, Ragnar, Jensen, Holger, Johansson, Bengt R, Lindegren, Sture, Olsson, Marita, Palm, Stig, Warnhammar, Elisabet, Jacobsson, Lars
    International Journal of Radiation Oncology, Biology and Physics, 15 November 2006, Vol.66(4) [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′) 2

    Elgqvist, Jörgen, Andersson, Håkan, Bernhardt, Peter, Bäck, Tom, Claesson, Ingela, Hultborn, Ragnar, Jensen, Holger, Johansson, Bengt R, Lindegren, Sture, Olsson, Marita, Palm, Stig, Warnhammar, Elisabet, Jacobsson, Lars
    International journal of radiation oncology, biology, physics, 2006, Vol.66(4), pp.1228-1237 [Revue évaluée par les pairs]
    ScienceDirect Journals (Elsevier)
    Disponible
    Plus…
    Titre: Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′) 2
    Auteur: Elgqvist, Jörgen; Andersson, Håkan; Bernhardt, Peter; Bäck, Tom; Claesson, Ingela; Hultborn, Ragnar; Jensen, Holger; Johansson, Bengt R; Lindegren, Sture; Olsson, Marita; Palm, Stig; Warnhammar, Elisabet; Jacobsson, Lars
    Sujet: Ovarian Cancer ; Radioimmunotherapy ; Dosimetry ; Mx35 ; Astatine ; Ovarian Cancer ; Radioimmunotherapy ; Dosimetry ; Mx35 ; Astatine ; Medicine
    Description: Purpose: To elucidate the therapeutic efficacy of α-radioimmunotherapy of ovarian cancer in mice. This study: (i) estimated the minimum required activity (MRA), giving a reasonable high therapeutic efficacy; and (ii) calculated the specific energy to tumor cell nuclei and the metastatic cure probability (MCP) using various assumptions regarding monoclonal-antibody (mAb) distribution in measured tumors. The study was performed using the α-particle emitter Astatine-211 ( 211At) labeled to the mAb MX35 F(ab′) 2. Methods and Materials: Animals were inoculated intraperitoneally with ∼1 × 10 7 cells of the cell line NIH:OVCAR-3. Four weeks later animals were treated with 25, 50, 100, or 200 kBq 211At-MX35 F(ab′) 2 ( n = 74). Another group of animals was treated with a nonspecific mAb: 100 kBq 211At-Rituximab F(ab′) 2 ( n = 18). Eight weeks after treatment the animals were sacrificed and presence of macro- and microscopic tumors...
    Fait partie de: International journal of radiation oncology, biology, physics, 2006, Vol.66(4), pp.1228-1237
    Identifiant: 0360-3016 (ISSN); 1879-355X (E-ISSN); 10.1016/j.ijrobp.2006.07.003 (DOI)